The investigation into the death of Jim Irsay, former owner of the Indianapolis Colts, reveals troubling connections that highlight the complexities of treating addiction with controversial methods. Irsay, who died at the age of 65 in May, was undergoing treatment with Dr. Harry Haroutunian, an addiction recovery specialist. Citing unnamed sources and documents, the Washington Post reported that Haroutunian is now the subject of an FBI probe. The focus of this inquiry includes Irsay’s use of both illegal and prescription substances during his final months.
According to the report, the federal grand jury is particularly interested in exploring the nature of Irsay’s relationship with Haroutunian and their treatment strategy involving ketamine. This drug, often used in surgical settings, has recently gained attention for its controversial application in addiction recovery. Ketamine’s use in treating addiction surfaced notably after actor Matthew Perry’s death, which highlighted the risks associated with its administration in non-hospital settings.
Haroutunian’s involvement in Irsay’s care raises significant questions. The physician signed Irsay’s death certificate, attributing his death to cardiac arrest, pneumonia, and underlying heart issues. Notably, no autopsy was performed, which has fueled speculation regarding the quality and oversight of Irsay’s treatment. The lack of an autopsy leaves room for unanswered questions that the ongoing investigation aims to address.
Reports indicate that Irsay was receiving opioids as well as ketamine in dosages that alarmed those close to him. Haroutunian expressed a personal commitment to Irsay, stating, “I dedicated 18 months of my life to try to care for him… as a brother.” Such deep involvement suggests a complicated relationship that may have blurred the lines between professional care and personal attachment, with potentially dangerous implications.
The Colts organization has acknowledged awareness of the investigation but reports that they have not yet been contacted by the FBI or served with any subpoenas. Meanwhile, the Drug Enforcement Administration (DEA) is collaborating with the FBI in the investigation, signaling a serious approach to uncovering the details surrounding Irsay’s final months.
This investigation into Irsay’s death could have broader implications, especially as it follows high-profile cases highlighting the risks of using ketamine in rehabilitation. The circumstances of Irsay’s treatment raise urgent questions about the responsibility of medical professionals when administering such medications, particularly in environments outside traditional medical care. The potential consequences of these inquiries may extend beyond Irsay’s legacy, impacting perceptions and practices surrounding addiction treatment nationwide.
"*" indicates required fields
